NBD AI Bulletin - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("the Company", SH 600196, close price: 50.29 yuan) announced on January 18 that the Company's shareholder Yao Fang's shareholding reduction plan has been completed, with 322,700 A-shares (about 0.013% of the Company's total shares) having been offloaded cumulatively at a price of between 50.300 yuan/share and 57.47 yuan/share.
According to the semi-annual report of 2020, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. mainly engages in pharmaceutical manufacturing and R&D, medical device services, and medical services, accounting for 71.37%, 18.83%, and 9.69% of its revenue, respectively.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s chairman is Wu Yifang, male, 52 years old, graduated from China Nanjing University of Science and Technology, MBA of St. Joseph's University, the United States.
Tips on "Stock Trends":
1. The number of shares held by northbound investors decreased by 1.3709 million in the past 30 days, representing 0.06% of the Company's circulating shares.
2. There was no institutional research on the Company in the past 30 days.
3. The last shareholding reduction announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was issued on September 30, 2020, and its share price rose 10.0% on the following trading day. The Company issued a total of 2 such announcements in the past 12 months.
(By Lan Suying)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.